397 related articles for article (PubMed ID: 7961113)
1. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.
Maruyama S; Iwashita T; Imai T; Funahashi H; Ceccherini I; Luo Y; Romeo G; Matsuo S; Matsuyama M; Takahashi M
Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113
[TBL] [Abstract][Full Text] [Related]
2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
[TBL] [Abstract][Full Text] [Related]
4. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X
J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.
Shirahama S; Ogura K; Takami H; Ito K; Tohsen T; Miyauchi A; Nakamura Y
J Hum Genet; 1998; 43(2):101-6. PubMed ID: 9621513
[TBL] [Abstract][Full Text] [Related]
6. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
[TBL] [Abstract][Full Text] [Related]
7. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
Sansó G; Domené HM; Iorcansky S; Barontini M
Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
Kambouris M; Jackson CE; Feldman GL
Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
[TBL] [Abstract][Full Text] [Related]
9. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
10. Absence of mutations at codon 768 of the RET proto-oncogene in sporadic and hereditary pheochromocytomas.
Yoshimoto K; Kimura T; Tanaka C; Moritani M; Iwahana H; Itakura M
Endocr J; 1996 Feb; 43(1):109-14. PubMed ID: 8732460
[TBL] [Abstract][Full Text] [Related]
11. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
Pausova Z; Soliman E; Amizuka N; Janicic N; Konrad EM; Arnold A; Goltzman D; Hendy GN
J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
[TBL] [Abstract][Full Text] [Related]
12. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer.
Blaugrund JE; Johns MM; Eby YJ; Ball DW; Baylin SB; Hruban RH; Sidransky D
Hum Mol Genet; 1994 Oct; 3(10):1895-7. PubMed ID: 7849720
[No Abstract] [Full Text] [Related]
13. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain.
Sánchez B; Robledo M; Biarnes J; Sáez ME; Volpini V; Benítez J; Navarro E; Ruiz A; Antiñolo G; Borrego S
J Med Genet; 1999 Jan; 36(1):68-70. PubMed ID: 9950371
[TBL] [Abstract][Full Text] [Related]
15. Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland.
Padberg BC; Schröder S; Jochum W; Kastendieck H; Roth J; Heitz PU; Komminoth P
Am J Pathol; 1995 Dec; 147(6):1600-7. PubMed ID: 7495285
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific mutations in the tyrosine kinase domain of the RET proto-oncogene in pheochromocytomas of sporadic type.
Yoshimoto K; Tanaka C; Hamaguchi S; Kimura T; Iwahana H; Miyauchi A; Itakura M
Endocr J; 1995 Apr; 42(2):265-70. PubMed ID: 7627271
[TBL] [Abstract][Full Text] [Related]
17. The RET proto-oncogene and cancer.
Donis-Keller H
J Intern Med; 1995 Oct; 238(4):319-25. PubMed ID: 7595167
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851
[TBL] [Abstract][Full Text] [Related]
19. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations.
Rossel M; Pasini A; Chappuis S; Geneste O; Fournier L; Schuffenecker I; Takahashi M; van Grunsven LA; Urdiales JL; Rudkin BB; Lenoir GM; Billaud M
Oncogene; 1997 Jan; 14(3):265-75. PubMed ID: 9018112
[TBL] [Abstract][Full Text] [Related]
20. RET oncogene mutations in medullary thyroid carcinoma in Mexican families.
González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B
Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
